SOX2 and non-small cell lung carcinoma: In addition, SOX2 small-interfering siRNA (siSOX2)-mediated knockdown overcame cisplatin resistance in NSCLC by regulating APE1 signaling, providing a new therapeutic target to overcome cisplatin resistance in NSCLC patients.